Neuroprotection and reduced gliosis by atomoxetine pretreatment in a gerbil model of transient cerebral ischemia.

Abstract

Atomoxetine (ATX) is a non-stimulant selective norepinephrine reuptake inhibitor that is widely used for the treatment of attention-deficit/hyperactivity disorder (ADHD). In this study, we firstly examined neuroprotective effects of pre- or post-treatment with 15 and 30 mg/kg ATX against ischemic damage in the gerbil hippocampal cornus ammonis 1 (CA1) region subjected to 5 min of transient cerebral ischemia using cresyl violet staining, neuronal nuclei immunohistochemistry and Fluoro-J B histofluorescence staining. We found that only pre-treatment with 30 mg/kg ATX protected CA1 pyramidal neurons from ischemic insult. In addition, pre-treatment with 30 mg/kg ATX, which had neuroprotective effect against ischemic damage, distinctly attenuated the activation of astrocytes and microglia in the ischemic CA1 region compared with the vehicle-treated ischemia group by glial fibrillary acidic protein (for astrocytes) and ionized calcium-binding adapter molecule 1 (for microglia) immunohistochemistry. In brief, our present results indicate that ATX has neuroprotective effect against transient cerebral ischemic insult and that the neuroprotective effect of ATX may be closely associated with attenuated glial activation.

• Authors: Joon Ha Park, Bich Na Shin, Bai Hui Chen, In Hye Kim, Ji Hyeon Ahn, Jeong-Hwi Cho, Hyun-Jin Tae, Jae-Chul Lee, Choong-Hyun Lee, Young-Myeong Kim, Yun Lyul Lee, Sung Koo Kim, Moo-Ho Won
• Journal: Journal of the neurological sciences (J Neurol Sci) Vol. 359 Issue 1-2 Pg. 373-80 (Dec 15 2015) ISSN: 1878-5883 [Electronic] Netherlands
• PMID: 26671145 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier B.V. All rights reserved.

Chemical References

• Fluoresceins
• Glial Fibrillary Acidic Protein
• Microfilament Proteins
• Neuroprotective Agents
• fluoro jade
• Atomoxetine Hydrochloride
• Phosphopyruvate Hydratase

Topics

• Analysis of Variance
• Animals
• Atomoxetine Hydrochloride (therapeutic use)
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Fluoresceins (metabolism)
• Gerbillinae
• Glial Fibrillary Acidic Protein (metabolism)
• Gliosis (etiology, prevention & control)
• Ischemic Attack, Transient (complications)
• Male
• Microfilament Proteins (metabolism)
• Neuroprotective Agents (therapeutic use)
• Phosphopyruvate Hydratase (metabolism)